ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,942.93
-1.21%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.425
0.19%
Brent Oil
82.275
0.37%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) ニュース

CLDX

Celldex Therapeutics (CLDX)

Celldex Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CLDX
日付受信時刻ニュースソース見出しコード企業名
2024/06/1506 : 34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1506 : 12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1505 : 02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1421 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1405 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1205 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/1205 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0806 : 23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0805 : 57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0805 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0605 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0605 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0605 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0505 : 01GlobeNewswire Inc.Celldex Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0406 : 51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0406 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0405 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0405 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0405 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0405 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/06/0222 : 01GlobeNewswire Inc.Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024NASDAQ:CLDXCelldex Therapeutics Inc
2024/05/3107 : 05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/3107 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/3106 : 47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/3104 : 20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/1521 : 01GlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
2024/05/0705 : 01GlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
2024/04/1721 : 01GlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CLDX

最近閲覧した銘柄

COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
AMEX
SPY
SPDR S&P 500
USOTC
BASFY
BASF (QX)
CCOM
US100
US Tech 100
AMEX
XLF
Financial Select Sector
NYSE
MCD
McDonalds
NASDAQ
GOOGL
Alphabet
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
COIN
BTCUSD
Bitcoin
NASDAQ
AAPL
Apple
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有